Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

M K Boisen; J S Johansen; Christian Dehlendorff; J S Larsen; K Osterlind; J Hansen; S E Nielsen; P Pfeiffer; Line Schmidt Tarpgaard; N H Holländer; N Keldsen; T F Hansen; B B Jensen; B V Jensen

doi:10.1093/annonc/mdt253

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

M K Boisen, J S Johansen, Christian Dehlendorff, J S Larsen, K Osterlind, J Hansen, S E Nielsen, P Pfeiffer, Line Schmidt Tarpgaard, N H Holländer, N Keldsen, T F Hansen, B B Jensen, B V Jensen

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.

Original language	English
Journal	Annals of Oncology
Volume	24
Issue number	10
Pages (from-to)	2554-2559
ISSN	0923-7534
DOIs	https://doi.org/10.1093/annonc/mdt253
Publication status	Published - Oct 2013

Keywords

Bevacizumab
Biomarker
Chemotherapy
Metastatic colorectal cancer
Primary tumor

Documents & Links

10.1093/annonc/mdt253

Cite this

Boisen, M. K., Johansen, J. S., Dehlendorff, C., Larsen, J. S., Osterlind, K., Hansen, J., Nielsen, S. E., Pfeiffer, P., Tarpgaard, L. S., Holländer, N. H., Keldsen, N., Hansen, T. F., Jensen, B. B., & Jensen, B. V. (2013). Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Annals of Oncology, 24(10), 2554-2559. https://doi.org/10.1093/annonc/mdt253

@article{eafd93ef02eb4b4abc9b99584b317b9c,

title = "Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer",

abstract = "There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.",

keywords = "Bevacizumab, Biomarker, Chemotherapy, Metastatic colorectal cancer, Primary tumor",

author = "Boisen, {M K} and Johansen, {J S} and Christian Dehlendorff and Larsen, {J S} and K Osterlind and J Hansen and Nielsen, {S E} and P Pfeiffer and Tarpgaard, {Line Schmidt} and Holl{\"a}nder, {N H} and N Keldsen and Hansen, {T F} and Jensen, {B B} and Jensen, {B V}",

year = "2013",

month = oct,

doi = "10.1093/annonc/mdt253",

language = "English",

volume = "24",

pages = "2554--2559",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "10",

}

Boisen, MK, Johansen, JS, Dehlendorff, C, Larsen, JS, Osterlind, K, Hansen, J, Nielsen, SE, Pfeiffer, P , Tarpgaard, LS, Holländer, NH, Keldsen, N, Hansen, TF, Jensen, BB & Jensen, BV 2013, 'Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer', Annals of Oncology, vol. 24, no. 10, pp. 2554-2559. https://doi.org/10.1093/annonc/mdt253

TY - JOUR

T1 - Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

AU - Boisen, M K

AU - Johansen, J S

AU - Dehlendorff, Christian

AU - Larsen, J S

AU - Osterlind, K

AU - Hansen, J

AU - Nielsen, S E

AU - Pfeiffer, P

AU - Tarpgaard, Line Schmidt

AU - Holländer, N H

AU - Keldsen, N

AU - Hansen, T F

AU - Jensen, B B

AU - Jensen, B V

PY - 2013/10

Y1 - 2013/10

N2 - There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.

AB - There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.

KW - Bevacizumab

KW - Biomarker

KW - Chemotherapy

KW - Metastatic colorectal cancer

KW - Primary tumor

U2 - 10.1093/annonc/mdt253

DO - 10.1093/annonc/mdt253

M3 - Journal article

C2 - 23864097

SN - 0923-7534

VL - 24

SP - 2554

EP - 2559

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

Abstract

Keywords

Documents & Links

Fingerprint

Cite this